Genmab AS (CHIX:GMABC) Cyclically Adjusted Book per Share: kr335.48 (As of Mar. 2026)


CHIX:GMABC Genmab AS CHIX:GMABC
95 GF Score
Price kr1,671.50
GF Value kr2,051.58
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Book per Share?

Genmab AS CHIX:GMABC 95 Cyclically Adjusted Book per Share is kr335.48 as of Mar. 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 95/100 and a GF Value™ of kr2,051.58 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Genmab AS's adjusted book value per share for the three months ended in Mar. 2026 was kr598.391. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr335.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Book Growth Rate was 20.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Genmab AS was 40.30% per year. The lowest was 24.60% per year. And the median was 33.25% per year.

As of today (2026-07-04), Genmab AS's current stock price is kr1671.50. Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was kr335.48. Genmab AS's Cyclically Adjusted PB Ratio of today is 4.98.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.91.


Genmab AS  (CHIX:GMABc) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1671.50/335.48
=4.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.91.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Genmab AS Cyclically Adjusted Book per Share Related Terms


Genmab AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Book per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.49 169.65 207.86 261.45 327.54

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 285.43 291.98 293.18 327.54 335.48

CHIX:GMABC vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


CHIX:GMABC
95GF Score
Genmab AS CHIX:GMABC
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=598.391/121.6800*121.6800
=598.391

Current CPI (Mar. 2026) = 121.6800.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 62.022 100.600 75.018
201609 65.352 100.200 79.362
201612 79.944 100.300 96.985
201703 82.491 101.200 99.185
201706 90.784 101.200 109.156
201709 88.502 101.800 105.785
201712 104.053 101.300 124.987
201803 106.472 101.700 127.390
201806 110.815 102.300 131.808
201809 114.862 102.400 136.488
201812 131.293 102.100 156.471
201903 131.206 102.900 155.152
201906 135.672 102.900 160.433
201909 191.279 102.900 226.189
201912 218.131 102.900 257.941
202003 221.135 103.300 260.481
202006 273.865 103.200 322.906
202009 281.591 103.500 331.053
202012 295.459 103.400 347.693
202103 302.680 104.300 353.117
202106 304.858 105.000 353.287
202109 321.000 105.800 369.180
202112 338.376 106.600 386.244
202203 350.217 109.900 387.756
202206 368.046 113.600 394.224
202209 402.326 116.400 420.576
202212 421.840 115.900 442.877
202303 424.249 117.300 440.091
202306 441.697 116.400 461.733
202309 471.413 117.400 488.599
202312 490.352 116.700 511.277
202403 495.032 118.400 508.746
202406 485.686 118.500 498.720
202409 505.732 118.900 517.557
202412 575.798 118.900 589.261
202503 576.839 120.200 583.942
202506 557.588 120.700 562.115
202509 593.997 121.600 594.388
202512 605.440 121.200 607.838
202603 598.391 121.680 598.391

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr335.48 mean?
Genmab AS (CHIX:GMABC) has a Cyclically Adjusted Book per Share of kr335.48 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Book per Share too high?
Genmab AS's current Cyclically Adjusted Book per Share is kr335.48. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Book per Share of kr335.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Book per Share is kr335.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,051.58, compared to a current price of kr1,671.50 — trading 18.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is kr335.48. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Cyclically Adjusted Book per Share is kr335.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr1,671.50 is trading 18.5% below its estimated GF Value™ of kr2,051.58. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for CHIX:GMABC:

  • Cyclically Adjusted Book per Share: kr335.48
  • GF Value™: kr2,051.58 vs. price of kr1,671.50 (18.5% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for CHIX:GMABC

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,671.50
Price
kr2,051.58
GF Value